Viking Therapeutics, Inc. financials
Key figures from Viking Therapeutics, Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net income | -$183M | -$91M | -101.8% |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $0 | -$360M | — | — | -$3.19 |
| FY Dec 2024 | $0 | -$110M | — | — | -$1.01 |
| FY Dec 2023 | $0 | -$86M | — | — | -$0.91 |
| FY Dec 2022 | $0 | -$69M | — | — | -$0.90 |
| FY Dec 2021 | $0 | -$55M | — | — | -$0.71 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.